This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Array Genomics, Assistance Publique-Hopitaux De Paris, Centre Hospitalier Régional Universitaire De Tours. Active years: 2014-2024.
Company Filing History:
2 out of 2 
1 out of 331 
1 out of 5 
Years Active: 2014-2024
Title: Olivier Cussenot: Innovator in Cancer Detection
Introduction
Olivier Cussenot is a prominent inventor based in Paris, France. He has made significant contributions to the field of cancer detection, particularly in prostate and bladder cancers. With a total of 3 patents, his work focuses on innovative methods for diagnosing and predicting cancer recurrence.
Latest Patents
Cussenot's latest patents include a groundbreaking method for identifying indolent prostate cancer. This method involves providing a sample from a subject, determining the TMPRSS/ERG fusion status, and measuring the expression levels of various prostate cancer markers. By comparing the molecular signature to a reference signature, the method predicts the risk of cancer recurrence in the subject. Additionally, he has developed a method for the urinary detection of bladder cancer. This invention utilizes a DNA chip to detect transitional type bladder carcinomas in urine samples, allowing for the determination of tumor grade.
Career Highlights
Throughout his career, Olivier Cussenot has worked with notable organizations such as Array Genomics and Sorbonne Université. His expertise in molecular diagnostics has positioned him as a leader in the field of cancer research and innovation.
Collaborations
Cussenot has collaborated with esteemed colleagues, including François Lozach and Ian Jones. These partnerships have further enhanced his research and development efforts in cancer detection technologies.
Conclusion
Olivier Cussenot's contributions to cancer detection through his innovative patents demonstrate his commitment to advancing medical science. His work continues to impact the diagnosis and treatment of cancer, providing hope for improved patient outcomes.